| Towards personalized treatment for early stage HER2-positive breast cancer K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ... Nature Reviews Clinical Oncology 17 (4), 233-250, 2020 | 246 | 2020 |
| Recurrent ESR1–CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers J Veeraraghavan, Y Tan, XX Cao, JA Kim, X Wang, GC Chamness, ... Nature communications 5 (1), 4577, 2014 | 163 | 2014 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 131 | 2020 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 127 | 2020 |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ... Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019 | 126 | 2019 |
| HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ... Clinical Cancer Research 23 (17), 5123-5134, 2017 | 113 | 2017 |
| Radiation-triggered tumor necrosis factor (TNF) α-NFκB cross-signaling favors survival advantage in human neuroblastoma cells J Veeraraghavan, M Natarajan, S Aravindan, TS Herman, N Aravindan Journal of Biological Chemistry 286 (24), 21588-21600, 2011 | 91 | 2011 |
| Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells J Veeraraghavan, M Natarajan, P Lagisetty, V Awasthi, TS Herman, ... Pancreas 40 (7), 1107-1119, 2011 | 82 | 2011 |
| De-escalation of treatment in HER2-positive breast cancer: determinants of response and mechanisms of resistance J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ... The Breast 34, S19-S26, 2017 | 67 | 2017 |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical Cancer Research 27 (17), 4870-4882, 2021 | 65 | 2021 |
| The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance A Nardone, H Weir, O Delpuech, H Brown, C De Angelis, ML Cataldo, ... British journal of cancer 120 (3), 331-339, 2019 | 61 | 2019 |
| Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers JA Kim, Y Tan, X Wang, X Cao, J Veeraraghavan, Y Liang, DP Edwards, ... Nature communications 7 (1), 12991, 2016 | 61 | 2016 |
| Curcumin regulates low-linear energy transfer γ-radiation-induced NFκB-dependent telomerase activity in human neuroblastoma cells N Aravindan, J Veeraraghavan, R Madhusoodhanan, TS Herman, ... International Journal of Radiation Oncology* Biology* Physics 79 (4), 1206-1215, 2011 | 57 | 2011 |
| Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer V Sethunath, H Hu, C De Angelis, J Veeraraghavan, L Qin, N Wang, ... Molecular Cancer Research 17 (11), 2318-2330, 2019 | 56 | 2019 |
| Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications J Veeraraghavan, J Ma, Y Hu, XS Wang Breast cancer research and treatment 158, 219-232, 2016 | 50 | 2016 |
| Low-dose γ-radiation-induced oxidative stress response in mouse brain and gut: Regulation by NFκB–MnSOD cross-signaling J Veeraraghavan, M Natarajan, TS Herman, N Aravindan Mutation Research/Genetic Toxicology and Environmental Mutagenesis 718 (1-2 …, 2011 | 50 | 2011 |
| TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer MF Rimawi, P Niravath, T Wang, BN Rexer, A Forero, AC Wolff, R Nanda, ... Clinical Cancer Research 26 (4), 821-827, 2020 | 46 | 2020 |
| Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy C De Angelis, C Nagi, CC Hoyt, L Liu, K Roman, C Wang, Y Zheng, ... Clinical Cancer Research 26 (3), 738-745, 2020 | 46 | 2020 |
| A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer J Veeraraghavan, C De Angelis, R Mao, T Wang, S Herrera, AC Pavlick, ... Annals of Oncology 30 (6), 927-933, 2019 | 40 | 2019 |
| Neem leaf extract induces radiosensitization in human neuroblastoma xenograft through modulation of apoptotic pathway J Veeraraghavan, S Aravindan, M Natarajan, V Awasthi, TS Herman, ... Anticancer research 31 (1), 161-170, 2011 | 35 | 2011 |
Rachel SchiffBaylor College of Medicine在 bcm.edu 的电子邮件经过验证
